Literature DB >> 10586919

Hepatitis A in Latin America: a changing epidemiologic pattern.

R Tapia-Conyer1, J I Santos, A M Cavalcanti, E Urdaneta, L Rivera, A Manterola, M Potin, R Ruttiman, J Tanaka Kido.   

Abstract

In a multicenter study, hepatitis A virus (HAV) seroprevalence was surveyed in six countries in Latin America in which in 12,000 subjects were stratified for age. The highest rates of seroprevalence were recorded in the Dominican Republic (89.0%) and Mexico (81.0%), with lower rates in Brazil (64.7%), Chile (58.1%), Venezuela (55.7%), and Argentina (55.0%). The seroprevalence of HAV in children between 1 and 5 years of age was less than 50%, except in the Dominican Republic. In the 5-10-year-old age group, seroprevalence rates have also decreased compared with previous reports. This suggests that the epidemiology is shifting from high to intermediate endemicity, with the population susceptible to HAV infection shifting from children to adolescents and adults. Furthermore, data from Brazil, Argentina, and Mexico show that HAV seroprevalence is significantly lower in people living in medium and high socioeconomic conditions. This study suggests the need for appropriate vaccination programs to be implemented targeting children, adolescents, and adults, particularly in higher socioeconomic groups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586919     DOI: 10.4269/ajtmh.1999.61.825

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

1.  Development and evaluation of a broadly reactive TaqMan assay for rapid detection of hepatitis A virus.

Authors:  N Jothikumar; T L Cromeans; M D Sobsey; B H Robertson
Journal:  Appl Environ Microbiol       Date:  2005-06       Impact factor: 4.792

2.  Acute viral hepatitis in the United States-Mexico border region: data from the Border Infectious Disease Surveillance (BIDS) Project, 2000-2009.

Authors:  Philip R Spradling; Jian Xing; Alba Phippard; Maureen Fonseca-Ford; Sonia Montiel; Norma Luna Guzmán; Roberto Vázquez Campuzano; Gilberto Vaughan; Guo-liang Xia; Jan Drobeniuc; Saleem Kamili; Ricardo Cortés-Alcalá; Stephen H Waterman
Journal:  J Immigr Minor Health       Date:  2013-04

3.  Seroprevalence of hepatitis A virus in a cross-sectional study in Mexico: Implications for hepatitis A vaccination.

Authors:  Eduardo Lazcano-Ponce; Carlos Conde-Gonzalez; Rosalba Rojas; Rodrigo DeAntonio; Luis Romano-Mazzotti; Yolanda Cervantes; Eduardo Ortega-Barria
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

4.  Screening travelers for hepatitis A antibodies: an observational cost-comparison study of vaccine use.

Authors:  K K Lee; J Beyer-Blodget
Journal:  West J Med       Date:  2000-11

5.  The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis.

Authors:  Eduardo Lopez; Roberto Debbag; Laurent Coudeville; Florence Baron-Papillon; Judith Armoni
Journal:  J Gastroenterol       Date:  2007-03-12       Impact factor: 7.527

6.  Hepatitis A: Epidemiology and prevention in developing countries.

Authors:  Elisabetta Franco; Cristina Meleleo; Laura Serino; Debora Sorbara; Laura Zaratti
Journal:  World J Hepatol       Date:  2012-03-27

7.  Seroprevalence of Hepatitis A Virus, Hepatitis E Virus, and Helicobacter pylori in Rural Communities of the Bolivian Chaco, 2013.

Authors:  Irene Campolmi; Michele Spinicci; David Rojo Mayaregua; Herlan Gamboa Barahona; Antonia Mantella; Yunni Lara; Mimmo Roselli; Marianne Strohmeyer; Giampaolo Corti; Francesco Tolari; Joaquín Monasterio Pinckert; Harry R Dalton; Alessandro Bartoloni
Journal:  Am J Trop Med Hyg       Date:  2018-03-22       Impact factor: 2.345

8.  HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients.

Authors:  Albert J Czaja; Herschel A Carpenter; S Breanndan Moore
Journal:  Dig Dis Sci       Date:  2007-05-18       Impact factor: 3.199

9.  Model-based projections of the population-level impact of hepatitis A vaccination in Mexico.

Authors:  Thierry Van Effelterre; Rodrigo De Antonio-Suarez; Adrian Cassidy; Luis Romano-Mazzotti; Cinzia Marano
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

10.  Determinants of anti-hepatitis A antibody seroprevalence in 2- to 19-year-olds in the USA using NHANES 2007-2008.

Authors:  E Velasco-Mondragon; I Lindong; F Kamangar
Journal:  Epidemiol Infect       Date:  2011-05-09       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.